

Simultaneous Determination of Dofetilide and Amlodipine in Plasma by HPLC

Nisrin Kaddar^{1,2}, Sylvie Pilote¹, Simon Wong^{1,2}, Bertrand Caillier^{1,2}, Dany Patoine¹, Benoit Drolet^{1,2} and Chantale Simard^{1,2*}

¹University Institute of Cardiology and Pneumology Quebec, Research Centre, 2725, Chemin Sainte-Foy, Quebec QC, G1V 4G5, Canada
²Faculté de pharmacie, Pavillon Ferdinand-Vandry, 1050, Avenue of Medicine, Laval University, Quebec QC, G1V 0A6, Canada

Abstract

Dofetilide is a Class III antiarrhythmic drug useful in the management of atrial fibrillation but also known to prolong the QT interval on the ECG and to induce malignant ventricular tachyarrhythmias such as torsades de pointes (TDP). Drugs with calcium channel-blocking properties contribute to decrease the incidence of TDP. Amlodipine is a dihydropyridine calcium channel antagonist. Considering the potentially safe and useful combined use of dofetilide and amlodipine, we undertook drug biotransformation studies. To perform studies aiming to evaluate the possible pharmacokinetic interaction between these drugs, a unique sensitive HPLC assay able to quantify both drugs simultaneously was required. A sensitive and specific HPLC method using a tandem of UV/fluorescence detection was described for the analysis of amlodipine and dofetilide in plasma. The within-day and between-day precision studies showed good reproducibility with coefficients of variation less than 10% for all the analytes. The limits of detection were 0.5 ng/mL and 0.25 ng/mL and the limit of quantification were 1.7 ng/mL and 0.8 ng/mL for dofetilide and amlodipine respectively. This new method could be of great value in many applications such as *in vitro* and *in vivo* pharmacokinetic and drug-drug interactions studies, as well as therapeutic drug monitoring.

Keywords: High performance liquid chromatography; Tandem UV/fluorescence detection; Amlodipine; Dofetilide

Abbreviations: APD: Action Potential Duration; CV: Coefficient of Variation; EAD: Early after Depolarization; EC₅₀: 50% Effective Concentration; I_{Kr}: Rapid Component of the Delayed Rectifier Cardiac Potassium Current; IS: Internal Standard; LOD: Limit of Detection; LOQ: Limit of Quantification; Qc: Concentrations of Qualifiers; RSD: Relative Standard Deviation; TDP: Torsades De Pointes

Introduction

Dofetilide (N-[4-[2-[methyl[2-[4-(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-methanesulfonamide) is a Class III antiarrhythmic drug (TIKOSYN[®]) that selectively inhibits the rapid component of the delayed rectifier cardiac potassium current (I_{Kr}) with high potency (50% effective concentration (EC₅₀) in the nanomolar range) [1-3]. Dofetilide is considered to be a good adjunct to catheter-based ablation and alternative pharmacological approach for the treatment of atrial arrhythmias [4]. Dofetilide's chemical structure is shown in Figure 1.

Dofetilide prolongs the refractory period and action potential duration (APD) without having sodium channel-blocking effect, beta-blocking action or calcium channel-blocking activities [5,6]. Excessive prolongation of APD, an extension of dofetilide's pharmacological effect, presumably results from an abnormal increase of cytosolic Ca²⁺ concentration ([Ca²⁺]_i), which carries the risk of inducing early after depolarizations (EAD's) [7] and initiation of torsades de pointes (TDP), a malignant polymorphic ventricular tachycardia predisposing to

ventricular fibrillation and sudden death [8,9]. Dofetilide is known to prolong the QT interval on the ECG and to induce malignant ventricular tachyarrhythmias including TDP [6]. QT interval prolongation is directly related to the dose and plasma concentration of the drug [7]. Huang et al. [10], showed that CPU228, a derivative of dofetilide with calcium (Ca²⁺) antagonist properties, is able to block (I_{CaL}), contributing to decreased TDP, while leaving I_{Kr} blockade unaffected. Blockade of both I_{Kr} and I_{CaL} contributes to the major characteristics of complex Class III agents, such as amiodarone, dronedarone and azimilide [11-13]. All these agents cause a lower incidence of TDP and are more potent at suppressing ventricular arrhythmias. Along those lines, our laboratory has recently shown that amlodipine, a calcium channel blocker, reduces the monophasic APD-prolonging effect of dofetilide [14], suggesting a potential reduction of its proarrhythmic properties and the possible rationale for using both drugs simultaneously.

Amlodipine besylate (NORVASC[®]) is chemically described as 3-ethyl-5-methyl (±)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate monobenzenesulphonate. Its structure is shown in Figure 2. Amlodipine is a dihydropyridine calcium antagonist that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle [15,16].

Keeping in mind the potentially useful and safe combined use of dofetilide and amlodipine, we undertook biotransformation studies to test if there is any significant drug interaction between these two drugs.





Figure 1: Structure of dofetilide.

***Corresponding author:** Chantale Simard, University Institute of Cardiology and Pneumology Quebec, Research Centre, chemin Sainte-Foy, Quebec QC, G1V 4G5, Canada, Tel: 418-656-8711 ext: 3072; Fax: 418-656-4509; E-mail: chantale.simard@pha.ulaval.ca

Received July 05, 2013; Accepted July 25, 2013; Published July 29, 2013

Citation: Kaddar N, Pilote S, Wong S, Caillier B, Patoine D, et al. (2013) Simultaneous Determination of Dofetilide and Amlodipine in Plasma by HPLC. J Chromatograph Separat Techniq 4: 192. doi:10.4172/2157-7064.1000192

Copyright: © 2013 Kaddar N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



It has been shown that the majority of adverse drug-drug interactions, which have a pharmacokinetic origin, can be understood in terms of alteration of cytochrome P450-catalyzed reactions [17]. The human CYP3A subfamily plays a dominant role in the metabolic elimination of more than 50% of commercially available drugs [17-19]. The CYP3A4 enzyme is expressed in the liver and small intestine and contributes to first-pass effect [18,20]. The major metabolic route of dofetilide (N-demethylation) is mediated by CYP3A4 in human liver microsomal preparations [21]. Moreover, it has been shown *in vivo* and *in vitro* that amlodipine can be an inhibitor of CYP3A4 [22,23]. In order to study the possible pharmacokinetic interaction between dofetilide and amlodipine, a unique sensitive HPLC assay that is able to quantify both drugs was then required.

Several analytical methods for quantifying dofetilide (LCMS [24], HPLC [21,25] and RIA [26] or amlodipine (HPLC [9,27-31], HPLC with radioactivity detection [32], HPLC with electrochemical detection [33], LCMS [34-36], GCMS [37] and GC with electron capture detection [38] in biological fluids have been reported. Unfortunately, all of these described methods do not allow the quantification of both drugs in the same run. In contrast, our work described a rapid and sensitive HPLC method, which enables to determine plasma concentrations of dofetilide and amlodipine simultaneously, using fluorescence detection.

Experimental

Experiments were performed in accordance with our institutional guidelines on animal use in research. Animals were housed and maintained in compliance with the *Guide to the Care and Use of Experimental Animals* of the Canadian Council on Animal Care.

Chemicals and reagents

Dofetilide and amlodipine besylate were kindly provided by Pfizer (Groton, CT, USA). Nortryptiline, used as internal standard (IS), phosphoric acid, dimethylsulfoxide (DMSO), triethylamine, 1-heptane sodium sulfonate and ammonium phosphate monobasic were purchased from Sigma (St. Louis, MO, USA). Acetonitrile and methanol were purchased from either Fisher Scientific (Ottawa, ON, Canada) or Sigma. Human, guinea pig and mouse K2-EDTA plasma were purchased from Innovative Research Inc. (Novi, MI, USA).

Stock and standard solutions

Stock solutions were prepared by dissolving 100 mg of dofetilide and 20 mg of amlodipine besylate in 10 mL of DMSO to get a final concentration of 10 mg/mL and 2 mg/mL respectively. Aliquots were subsequently diluted with DMSO to yield stock solutions of 100 µg/mL and 200 µg/mL respectively. With subsequent serial dilutions in DMSO, two calibration curves from 0.5 to 50 ng/µL (0.5-1-2.5-5-7.5-

10-25-50) for dofetilide and 1 to 100 ng/µL (1-2.5-5-7.5-10-25-50-100) for amlodipine were constructed. Different known concentrations of qualifiers (Qc) were also prepared. Working solution of internal standard nortryptiline was prepared in methanol to a final concentration of 0.66 mg/mL. The stock and working solutions were stored at -20°C. All the different drugs individually injected in the HPLC system were not containing contaminants under the analytical conditions used. This verification procedure was performed each time the HPLC system was started.

Plasma standard preparation and extraction procedures

In 12×75 mm test tubes, known amounts of dofetilide (5-10-25-50-75-100-250-500 ng), amlodipine (10-25-50-75-100-250-500-1000 ng) and nortryptiline as internal standard (33 µg) were added to 400 µL of guinea pig K2-EDTA plasma. The preparation was alkalized with 600 µL of carbonate buffer 0.2 M pH 9.2 [39], vortexed during 10 s and loaded into the pre-activated SPE cartridges Strata-X 33 µm (Phenomenex, Torrance, CA, USA). The pre-activation was made by adding 1 mL of methanol for activation and 1 mL of H₂O for equilibration. Then, the cartridges were washed with 1 mL (H₂O:NH₄OH, 95:5). After low vacuum application (<300 mmHg), samples were eluted with 1 mL (methanol: formic acid, 98:2) and evaporated to dryness under light stream of nitrogen at 37°C. The residue was reconstituted in 150 µL of buffer A of the mobile phase and centrifuged at 4000 rpm for 10 min at 4°C. An aliquot (50 µL) of the supernatant was injected into the HPLC system.

Instrumentation

Apparatus and chromatographic conditions: The HPLC was performed at room temperature with a complete Prominence Shimadzu system (Columbia, MD, USA) consisting of an automatic sample injector model SIL-20AC_{HT}, a pump model LC-20AT, a fluorescence detector models RF-10Ax1 and an ultraviolet (UV) detector model SPD-20A. The software EZ-Start (Columbia, MD, USA) was used for acquisition, storage and analysis of data. Ultrasphere ODS 5 µm column, 250 mm×4.6 mm (Phenomenex, Torrance, CA, USA) and Bondapak C18 guard column (Waters, Mississauga, ON, Canada) were used to perform the separation.

Chromatographic separation was achieved at room temperature and was based on a method previously described [31]. The modified mobile phase consisted of buffer A: methanol/ammonium phosphate 20 mM, 1-heptane-sulfonate 5 mM filtered through 0.45 µm filter/acetonitrile (19/70/11) containing 0.08% (wt/vol) triethylamine and adjusted to pH 7.1 with phosphoric acid and buffer B: methanol/ammonium phosphate 20 mM, 1-heptane-sulfonate 5 mM filtered through 0.45 µm filter/acetonitrile (38/42/20) containing 0.08% (wt/vol) triethylamine and adjusted to pH 7.1 with phosphoric acid. The buffers were degassed by ultrasonication before use. A flow-rate of 1.1 mL/min was imposed. The elution gradient used was as follow: 0-15 min, 0-100% buffer B; 15-35 min, 100% buffer B; 35-38 min, 100-0% buffer B; 38-43 min 100% buffer A. The peaks of dofetilide and amlodipine were monitored in fluorescence at wavelengths determined by scanning spectrofluorimeter: 228 nm excitation/325 nm emission and 366 nm excitation/457 nm emission respectively. To optimize the detection, the following program of wavelengths monitoring was used: 0-8 min, 228 nm excitation/325 nm emission, sensitivity magnification X1; 8-16 min, 228 nm excitation/325 nm emission, sensitivity magnification X32; 16-43 min, 366 nm excitation/457 nm emission, sensitivity magnification X512. The peak of internal standard was monitored in UV at 238 nm.

Recovery and matrix effect

Extraction recoveries were determined for three Qc points of dofetilide and amlodipine from the ratio of the analyte peak height in samples spiked before extraction compared to the corresponding peak height in untreated samples prepared in neat solution. Briefly, 10 μ L of standard solutions of dofetilide (10, 100, 500 ng) and amlodipine (25, 500, 1000 ng) were added to two sets of three tubes containing the IS (50 μ L). To the first set, 400 μ L of guinea pig plasma were added, vortexed and extracted according to the sample procedures described above. The second set was adjusted to the same volume with mobile phase. After injection of 40 μ L into the HPLC system, the heights of the peaks of the unextracted and extracted samples were compared. K₂-EDTA plasma from three different species (mouse, guinea pig and human) was also assessed to evaluate the matrix effect. The recovery was also evaluated in sample containing 1000 μ L of plasma.

Stability

Stability of the analytes in the plasma was determined using triplicates samples at three concentrations (10, 50, 100 ng/mL for dofetilide and 25, 100, 500 ng/mL for amlodipine) which were analyzed immediately after preparation and after the applied storage conditions. Three storage conditions were assessed: short-term storage at room temperature (4 and 24 hours), long-term storage at 4°C and -20°C (over 5 weeks). The autosampler stability of the extract was determined by analyzing the samples after 24 h of storage in the autosampler (set at +15°C). The concentrations of the samples were calculated against a calibration curve obtained from freshly prepared calibration standards. Stability of the stock and working solutions was also evaluated after short and long-term storage at -20°C at different time intervals. Experiments were run in triplicate and average peak ratio (\pm RSD) was considered in calculations.

Methods

Specificity: Specificity was performed by analyzing 5 blank plasma samples from three different species to evaluate possible endogenous interference at the retention times of the analytes and of the internal standard. The sample preparation and chromatographic conditions were optimized to guarantee that no interference incurred at the retention times of the tested compounds. The specificity was also demonstrated in another matrix by analyzing the supernatant of microsomal incubations.

Linearity: Five series of calibration curves were prepared. The sample preparation and HPLC analyses were performed as described and detailed in sections 2.3 and 2.4. Calibration curves were constructed by plotting the measured peak height ratios (analyte/IS) versus the amount of dofetilide or amlodipine added. The data were subjected to least-squares linear regression analysis. The linearity of plasma spiked curves was established by calculating correlation coefficients (r^2) and the percent deviation (%DEV).

Precision and accuracy: Sensitivity was evaluated by limit of detection (LOD) and limit of quantification (LOQ) values. The LOD and LOQ were estimated by two approaches using ICH Harmonised Tripartite Guideline. The approach based on signal-to-noise ratio and the visual evaluation of minimum level detected were applied. Replicates of blank extract (n=15) and sample spiked with 5 ng of dofetilide (n=10) and 10 ng of amlodipine (n=10) were measured.

Accuracy and precision were evaluated by determining amlodipine and dofetilide at three different concentrations of Qc samples. Intraday variability in the analysis of dofetilide and amlodipine was assessed by

repeated analyses (n=10) of fixed amounts of dofetilide (10, 25 and 100 ng) and amlodipine (25, 100 and 500 ng) in 400 μ L of plasma. Interday precision was determined by repeated analyses of the three amounts of dofetilide (10, 25 and 100 ng) and three amounts of amlodipine (25, 100 and 500 ng) in 400 μ L of plasma on five consecutive days. Accuracy was defined as the percent difference between the mean observed concentration and the nominal concentration. The precision was calculated as percent coefficient of variation (CV).

In vivo pharmacokinetic application

A single dose of dofetilide 0.1 mg/kg and amlodipine 0.5 mg/kg in water suspension was administered by oral gavage to conscious male Hartley guineapigs (Charles River Laboratories, Montreal, QC, Canada) weighing 800-1200 g (n=3). Animals were anesthetized by isoflurane inhalation (4 L/min of isoflurane 3% to induce anesthesia, and 1 L/min to maintain it) and jugular blood samples (2 mL) were drawn in tubes containing K₂-EDTA at pre-defined time points after administration. Centrifugation was performed at 4000 rpm for 25 min at 4°C and plasma was separated and stored at -20°C until analyzed. The extraction and determination of dofetilide and amlodipine in 1.0 mL of plasma were performed as previously described in the methods section.

Results

Chromatographic analysis

A representative chromatogram of a sample of guinea pig plasma containing dofetilide, amlodipine and the IS is shown in Figure 3. The average retention times were 13.5, 29 and 32 min for dofetilide, amlodipine and the IS (nortryptiline), respectively. Under the chromatographic conditions described, no endogenous interfering plasma materials were detected. The run time of 43 min allowed a good separation of the three peaks with complete return to baseline.

Recovery

Recoveries of dofetilide, amlodipine and nortryptiline were determined by comparing the peak heights of the solid-phase extracted standards from plasma and those from the unextracted samples. The percent recovery of the method was found to be $95.8 \pm 3.0\%$ for




Figure 3: Typical chromatograms of a blank plasma spiked with 5 ng dofetilide, 10 ng amlodipine and internal standard [plain line] and a blank plasma spiked with 50 ng dofetilide, 75 ng amlodipine and internal standard [dash line] (upper chromatogram) and a control blank plasma (lower chromatogram). The chromatographic conditions for detection (box) and buffer gradient (dotted line) were pointed out.

	Recovery (%)							
	For dofetilide at three concentrations (n=3)				For amlodipine at three concentrations (n=3)			
	10 ng/mL	50 ng/mL	100 ng/mL	Mean recovery	25 ng/mL	100 ng/mL	500 ng/mL	Mean recovery
Short-term storage								
24 h (4°C)	99.47	96.55	100.87	98.96 ± 1.27	105.86	101.90	95.64	101.13 ± 2.97
24 h (-20°C)	94.06	85.14	108.88	96.04 ± 6.91	98.45	95.86	99.51	97.94 ± 1.09
Mid-term storage								
1 week (4°C)	102.84	97.61	98.77	99.74 ± 1.58	91.78	98.07	96.27	95.37 ± 1.87
1 week (-20°C)	104.92	102.31	104.44	103.89 ± 0.80	98.71	100.81	100.90	100.14 ± 0.72
Long-term storage								
5 weeks (4°C)	81.09	87.37	76.51	81.66 ± 3.15*	72.40	81.80	76.51	76.90 ± 2.72*
5 weeks (-20°C)	80.32	85.15	79.03	81.50 ± 1.87*	87.05	90.12	91.54	89.57 ± 1.33*

*P<0.001

Table 1: Stability of dofetilide and amlodipine in plasma samples.

Spiked concentration (ng/400 µL)	Observed concentration (mean* ± S.D.*)	Coefficient of variation (%)	Accuracy (%)
Intra-day Dofetilide (n=10)			
10	10.63 ± 0.50	4.73	106.29
25	23.55 ± 0.72	3.06	94.18
100	99.89 ± 3.76	3.76	99.86
Intra-day Amlodipine (n=10)			
25	21.35 ± 1.67	7.82	85.40
100	90.59 ± 2.96	3.26	90.59
500	513.09 ± 21.61	4.21	102.62

*Standard deviation

*Linear regression equations used: y=0.0060x for dofetilide and y=0.0017x for amlodipine

Table 2: Intra-day precision and accuracy for determination of dofetilide and amlodipine in human plasma by the HPLC method.

Spiked concentration (ng/400 µL)	Observed concentration (mean* ± S.D.*)	Coefficient of variation (%)	Accuracy (%)
Inter-day Dofetilide (n=5)			
10	10.20 ± 0.14	10.30	102
25	23.36 ± 0.47	2.01	93.4
100	98.27 ± 5.14	5.23	98.3
Inter-day Amlodipine (n=5)			
25	21.16 ± 2.17	10.26	84.65
100	101.87 ± 9.06	8.89	101.87
500	536.25 ± 50.44	9.41	107.25

*Standard deviation

*Linear regression equations used: y=0.0060x for dofetilide and y=0.0017x for amlodipine

Table 3: Inter-day precision and accuracy for determination of dofetilide and amlodipine in human plasma by the HPLC method.

dofetilide, 76.5 ± 2.9% for amlodipine and 75.4 ± 1.6% for nortryptiline with relative standard deviation (RSD) ≤ 4%. The variability of extraction recovery was investigated from different plasma samples and from microsomal supernatant. No difference in extraction recoveries was found when using mouse, human and guinea pig plasma samples and microsomal supernatant.

Method validation

Stability: Table 1 shows stability data in plasma. There is no statistically significant difference between plasma amlodipine and dofetilide samples kept at +4°C and -20°C compared to nominal for one week. Plasma amlodipine and dofetilide levels were reduced to 76.9 ± 2.7% and 81.7 ± 3.2% of nominal, respectively, when stored at 4°C for 5 weeks. A long-term storage of 5 weeks at -20°C allowed a recovery of 89.6 ± 1.4% and 81.5 ± 1.9% for plasma amlodipine and dofetilide levels respectively, when compared to nominal.

Additionally, concentrations of analytes and internal standard were stable in processed (extracted) plasma samples at +15°C for 24 hours.

No statistically significant degradation of dofetilide and amlodipine was observed in stock and working solutions stored at -20°C for 8 weeks.

Linearity and sensitivity: Five series of eight-point calibration curves (prepared on five different days) were constructed for both drugs over the range of 5 to 500 ng for dofetilide and 10 to 1000 ng for amlodipine. Equations were determined by least-squares linear regression analyses. The mean equation were y=0.0060x ± 0.0003 (r²=0.999 ± 0.001) for the determination of dofetilide and y=0.0017x ± 0.0002 (r²=0.998 ± 0.001) for the determination of amlodipine. The relative standard deviation values of the slope were 5.2% for dofetilide and 12.7% for amlodipine. For each calibration curves, the intercept was not significantly different from zero (χ²<3.84). The method was linear across the whole range of concentrations allowing the possibility to extend the method to different purposes.

Accuracy and precision: The limits of detection (LOD) defined for dofetilide and amlodipine were 0.5 ng/mL and 0.25 ng/mL and the limits of quantification (LOQ) were 1.7 ng/mL and 0.8 ng/mL for dofetilide and amlodipine respectively.

Intraday and interday expressed as a coefficient of variation were less than 5.4% and 10.1% for dofetilide and amlodipine respectively. For both intraday and interday, the mean accuracy value was 99.0 ± 4.9% for dofetilide and 95.4 ± 9.7 for amlodipine (Tables 2 and 3).

In vivo pharmacokinetic application

Typical chromatogram of guinea pig plasma after a single oral gavage of dofetilide 0.1 mg/kg and amlodipine 0.5 mg/kg is shown in Figure 4. It shows the measured concentrations of both dofetilide and amlodipine at three different sampling times in three different guinea pigs after a single oral gavage dose of dofetilide 0.1 mg/kg and amlodipine 0.5 mg/kg. These *in vivo* data are validating the method described in the present paper and confirming its usefulness for pre-clinical and eventually, clinical purposes.

Discussion

We developed a new HPLC method with tandem fluorescence/UV detection, allowing the simultaneous quantification of two structurally different drugs (dofetilide and amlodipine) in plasma. The validity and usefulness of this new method was further confirmed by *in vivo* animal experiments.

Other more sensitive methods use GC and LC-MS techniques.




Figure 4: Typical chromatogram from guinea pig plasma after a single oral gavage dose of dofetilide 0.1 mg/kg and amlodipine 0.5 mg/kg.

The thermal instability of the drugs under GC conditions represents a serious concern. The present HPLC assay has the advantage of eliminating the risk of thermal degradation of drugs. Methods using MS are very sensitive and have low LOQ. However, these methods are not available for most laboratories due to cost and equipment/expertise requirements.

As previously mentioned, our laboratory showed that amlodipine, a calcium channel blocker, reduces the cardiac action potential-prolonging effect of dofetilide [14], suggesting a potential reduction of its proarrhythmic properties, thus suggesting a rationale for using these two drugs simultaneously. This HPLC method was therefore developed in order to further study *ex vivo* and *in vivo* drug-drug interaction between dofetilide and amlodipine in guinea pigs. Due to the limited plasma volume in the guinea pig, we developed this method requiring only 400 μ L of plasma. The method was not affected by increasing plasma volumes up to 1 mL. The previously reported methods for quantifying amlodipine and dofetilide often require elaborated extraction procedures and/or provide low compound recovery [25,28,31,33]. In contrast, our extraction procedure requires minimal sample preparation and allows a recovery >75% of amlodipine, dofetilide and nortriptyline from the same sample.

The present method was based on previous results described by Walker et al. and Yeung et al. [25,31] to quantify dofetilide and amlodipine respectively. Walker et al. [25] had a LOD of 2.5 ng/mL for dofetilide and Yeung et al. [31] had a LOQ of 2.5 ng/mL for amlodipine. Our method offers better results with a LOD of 0.5 ng/mL and 0.25 ng/mL and LOQ of 1.7 ng/mL and 0.8 ng/mL for dofetilide and amlodipine respectively.

Bahrami and Mirzaeei [30] described a HPLC method for the determination of amlodipine in human and its use in a pharmacokinetics study. This method was applied to the determination of the drug in plasma following a single amlodipine oral dose of 10 mg in 12 healthy volunteers. The LOD is 0.1 ng/mL and the LOQ is 0.25 ng/mL. With similar detection capabilities for amlodipine, we suggest our method could also be used for pharmacokinetic studies. Moreover, following repeated oral doses of amlodipine (10 mg once daily), Stangier and Su [40], showed that the C_{max} is 17.7 μ g/mL and the C_{trough} is 10 μ g/mL. On the other hand, following an oral twice daily dosing of dofetilide (500 μ g BID), Allen et al. [41] observed a C_{max} of 3.8 ng/mL and a C_{trough} of 1.24 ng/mL. Our method has a LOD of 0.25 ng/mL and a LOQ of 0.8 ng/mL. We are therefore confident that our method could be used

for pharmacokinetic interaction studies following coadministration of repeated doses of amlodipine and dofetilide in humans.

This newly developed assay is selective, presents a simple drug extraction procedure, requires a reduced plasma volume and allows the simultaneous detection and quantification of both dofetilide and amlodipine with better LOD and LOQ for both drugs than the previously described methods. Moreover, it is readily accessible without the use of more sophisticated analytical techniques requiring costly GC or MS installations.

As we demonstrated *ex vivo* in guinea pig hearts, the coadministration of both drugs could be beneficial in reducing the cardiac proarrhythmic potential of dofetilide [14]. Therefore, it could be very interesting to conduct a study in humans to confirm these exciting results. This newly developed high recovery HPLC method will allow the routine analysis of biological samples in pharmacokinetic studies involving the coadministration of dofetilide and amlodipine in humans.

Conclusion

In summary, the herein described assay is the first HPLC method that permits the determination of dofetilide and amlodipine in the same sample. This HPLC method provides a quick, simple, reproducible, and sensitive assay for the detection of both drugs in plasma. This method could be valuable in many applications; *in vitro* and *in vivo* pharmacokinetic and drug-drug interactions studies, as well as therapeutic drug monitoring.

Acknowledgements

This work was supported by a grant from the Pfizer Cardiovascular Research Award Program (Pfizer Canada) to CS and BD. BC was the recipient of a Doctoral studentship award from the Canadian Institutes of Health Research. CS and BD are recipients of Scholarship awards from the Fonds de la recherche en sant e du Qu ebec (FRSQ).

References

1. Carmeliet E (1992) Voltage- and time-dependent block of the delayed K⁺ current in cardiac myocytes by dofetilide. *J Pharmacol Exp Ther* 262: 809-817.
2. Jurkiewicz NK, Sanguinetti MC (1993) Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K⁺ current by dofetilide. *Circ Res* 72: 75-83.
3. Krafte DS, Volberg WA (1994) Voltage dependence of cardiac delayed rectifier block by methanesulfonamide class III antiarrhythmic agents. *J Cardiovasc Pharmacol* 23: 37-41.
4. Wells R, Khairy P, Harris L, Anderson CC, Balaji S (2009) Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. *Pacing Clin Electrophysiol* 32: 1313-1318.
5. Al-Dashti R, Sami M (2001) Dofetilide: a new class III antiarrhythmic agent. *Can J Cardiol* 17: 63-67.
6. Aktas MK, Shah AH, Akiyama T (2007) Dofetilide-induced long QT and torsades de pointes. *Ann Noninvasive Electrocardiol* 12: 197-202.
7. Mounsey JP, DiMarco JP (2000) Cardiovascular drugs. Dofetilide. *Circulation* 102: 2665-2670.
8. Clusin WT (2003) Calcium and cardiac arrhythmias: DADs, EADs, and alternans. *Crit Rev Clin Lab Sci* 40: 337-375.
9. Shorofsky SR, Balke CW (2001) Calcium currents and arrhythmias: insights from molecular biology. *Am J Med* 110: 127-140.
10. Huang ZJ, Dai DZ, Li N, Na T, Ji M, et al. (2007) Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. *Clin Exp Pharmacol Physiol* 34: 310-317.
11. Dai DZ, Hu HJ, Zhao J, Hao XM, Yang DM, et al. (2004) Blockade of L-type

- calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by CPU 86017. *Acta Pharmacol Sin* 25: 416-423.
12. Doggrel SA, Hancox JC (2004) Dronedaron: an amiodarone analogue. *Expert Opin Investig Drugs* 13: 415-426.
 13. Nemeč J, Shen WK (2003) Antiarrhythmic drugs: new agents and evolving concepts. *Expert Opin Investig Drugs* 12: 435-453.
 14. Caillier B, Pilote S, Patoine D, Levac X, Couture C, et al. (2012) Metabolic syndrome potentiates the cardiac action potential-prolonging action of drugs: a possible 'anti-proarrhythmic' role for amlodipine. *Pharmacol Res* 65: 320-327.
 15. Kass RS, Arena JP, Chin S (1989) Cellular electrophysiology of amlodipine: probing the cardiac L-type calcium channel. *Am J Cardiol* 64: 351-411.
 16. Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G (1989) Amlodipine, a new 1,4-dihydropyridine calcium antagonist with a particularly strong antihypertensive profile. *Am J Cardiol* 64: 211-341.
 17. Wienkers LC (2002) Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. *Eur J Pharm Sci* 15: 239-242.
 18. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev* 54: 1271-1294.
 19. Szklarz GD, Halpert JR (1997) Molecular modeling of cytochrome P450 3A4. *J Comput Aided Mol Des* 11: 265-272.
 20. Obach RS, Zhang QY, Dunbar D, Kaminsky LS (2001) Metabolic characterization of the major human small intestinal cytochrome p450s. *Drug Metab Dispos* 29: 347-352.
 21. Walker DK, Alabaster CT, Congrave GS, Hargreaves MB, Hyland R, et al. (1996) Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. *Drug Metab Dispos* 24: 447-455.
 22. Ma B, Prueksaritanont T, Lin JH (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. *Drug Metab Dispos* 28: 125-130.
 23. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, et al. (2005) Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. *Hypertens Res* 28: 223-227.
 24. Ollerstam A, Visser SA, Persson AH, Eklund G, Nilsson LB, et al. (2006) Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. *J Pharmacol Toxicol Methods* 53: 174-183.
 25. Walker DK, Smith DA, Stopher DA (1991) Liquid-liquid extraction and high-performance liquid chromatography for the determination of a novel antidysrhythmic agent (UK-68,798) in human urine. *J Chromatogr* 568: 475-480.
 26. Walker DK, Aherne GW, Arrowsmith JE, Cross PE, Kaye B, et al. (1991) Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay. *J Pharm Biomed Anal* 9: 141-149.
 27. Jeppesen P, Bruun J, Nielsen-Kudsk F (1998) Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. *Pharmacol Toxicol* 82: 250-256.
 28. Tatar S, Atmaca S (2001) Determination of amlodipine in human plasma by high-performance liquid chromatography with fluorescence detection. *J Chromatogr B Biomed Sci Appl* 758: 305-310.
 29. Zarghi A, Foroutan SM, Shafaati A, Khoddam A (2005) Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. *Farmaco* 60: 789-792.
 30. Bahrami G, Mirzaeei Sh (2004) Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studies. *J Pharm Biomed Anal* 36: 163-168.
 31. Yeung PK, Mosher SJ, Pollak PT (1991) Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. *J Pharm Biomed Anal* 9: 565-571.
 32. Smith DA, Rasmussen HS, Stopher DA, Walker DK (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. *Xenobiotica* 22: 709-719.
 33. Josefsson M, Norlander B (1996) Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection. *J Pharm Biomed Anal* 15: 267-277.
 34. Suchanova B, Kostianen R, Ketola RA (2008) Characterization of the in vitro metabolic profile of amlodipine in rat using liquid chromatography-mass spectrometry. *Eur J Pharm Sci* 33: 91-99.
 35. Bhatt J, Singh S, Subbaiah G, Shah B, Kambli S, et al. (2007) A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of amlodipine in human plasma. *Biomed Chromatogr* 21: 169-175.
 36. Nirogi RV, Kandikere VN, Mudigonda K, Shukla M, Maurya S (2006) Sensitive and rapid liquid chromatography/tandem mass spectrometry assay for the quantification of amlodipine in human plasma. *Biomed Chromatogr* 20: 833-842.
 37. Maurer HH, Arlt JW (1999) Screening procedure for detection of dihydropyridine calcium channel blocker metabolites in urine as part of a systematic toxicological analysis procedure for acidic compounds by gas chromatography-mass spectrometry after extractive methylation. *J Anal Toxicol* 23: 73-80.
 38. Beresford AP, Macrae PV, Stopher DA, Wood BA (1987) Analysis of amlodipine in human plasma by gas chromatography. *J Chromatogr* 420: 178-183.
 39. DELORY GE, KING EJ (1945) A sodium carbonate-bicarbonate buffer for alkaline phosphatases. *Biochem J* 39: 245.
 40. Stangier J, Su CA (2000) Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. *J Clin Pharmacol* 40: 1347-1354.
 41. Allen MJ, Nichols DJ, Oliver SD (2000) The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. *Br J Clin Pharmacol* 50: 247-253.